FENC Form 144 Notice — 1,775 Shares to Trade on NASDAQ 10/10/2025
Rhea-AI Filing Summary
Fennec Pharmaceuticals (FENC) filed a Form 144 notifying a proposed sale of 1,775 common shares with an aggregate market value of $16,401.00. The shares are scheduled for sale approximately on
Positive
- Full disclosure of proposed sale details including broker, share count, value, and planned sale date
- Acquisition method transparently stated as a stock option exercise with cash payment on
10/10/2025 - No prior sales reported in the past three months for the selling person
Negative
- None.
Insights
Small post‑exercise sale planned by an insider via market broker.
The notice records a proposed open‑market sale of
This transaction size represents a small fraction of the class base (27,831,698 outstanding), so it is unlikely to be price‑moving alone. Monitor trade execution on the listed exchange around
Filing follows Rule 144 disclosure and includes standard attestation.
The form includes the required representation that the seller is unaware of any undisclosed material adverse information and notes the possibility of a Rule 10b5‑1 trading plan if applicable. It names the executing broker and furnishes acquisition details (exercise from the issuer, cash payment).
From a compliance perspective, the clear dating of acquisition and planned sale simplifies rule‑144 eligibility review. If a trading plan or instruction date exists, it should be noted to confirm affirmative safe‑harbor timing.